血清S100B和神经元特异性烯醇化酶在脑血管意外患者中的检测及其临床意义

目的:探讨急性脑血管病患者血清S100B和神经元特异性烯醇化酶(NSE)的变化及其临床意义。方法:用双抗体夹心ELISA法检测58例脑梗死患者、36例脑出血患者治疗前和治疗后及30名健康人血清S100B和NSE水平。结果:脑梗死和脑出血患者的血清S100B、NSE浓度均高于对照组(P<0.001),脑梗死和脑出血患者的血清S100B、NSE浓度治疗后均低于治疗前(P<0.001);治疗前、脑梗死组患者的血清S100B浓度低于脑出血组患者(P<0.001),而脑梗死组患者的血清NSE浓度高于脑出血组患者(P<0.001)。结论:血清S100B和NSE检测可作为诊断早期脑损伤严重程度的指标;联合检测血清S100B和NSE,对鉴别诊断出血性脑病和缺血性脑病以及评价预后具有一定的临床意义。

The Detection and Significance of Sera S100B and NSE of Patients with Acute Cerebrovascular Disease

Objective: To explore the change and significance of serous S100B and NSE in patients with acute cerebrovascular disease Methods: The serous S100B and NSE level of 58 patients with acute cerebral infarction, 36 patients with cerebral hemorrhage both prior treatment and post-treatment stage were detected by ELISA method And the control data of 30 healthy persons were acquired with the same method Results: The serous S100B and NSE level of patients with acute cerebral infarction or cerebral hemorrhage were significantly higher than that with control group, P < 0001 Both acute cerebral infarction and cerebral hemorrhage patients, their sera S100B and NSE level in post-treatment stage were significance lower than that in prior treatment stage, P < 0001 However, in prior treatment stage, the serous S100B level of patients with acute cerebral infarction were lower than that with cerebral hemorrhage patients, and the sera NSE level of patients with acute cerebral infarction were higher than that with cerebral hemorrhage patients Conclusions: The examinations of serous S100B or NSE could be indices as diagnosis of early brain injury level The combinated examinations of serous S100B and NSE could be help to distinguish hemorrhagic or ischemic cerebrovascular disease and evaluate their prognosis